RL

RPG Life Sciences Ltd

Q2 FY27Pharmaceuticals & Biotechnology

RPG Life Sciences Q2 Results 2026: PAT ₹28 Cr (−24.3% YoY)

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹212Cr
+16.5% YoY
+8.2% QoQ
Net profit
₹28Cr
−24.3% YoY
−9.7% QoQ
Margin
19%
−2 pp YoY
−3 pp QoQ

RPG Life Sciences Ltd Q2 FY27 key numbers

Revenue
Q2 FY27 Adjusted EBITDA: ₹38.2 crore, margin 18.0%.

As stated in RPG Life Sciences Ltd's Q2 FY27 investor presentation · published 30 Oct 2026. Reported figures, not investment advice.

Based on RPG Life Sciences Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹3,004
Market cap₹5.0K Cr
P/E42.6

The short version

Q2 FY27 Revenue from Operations: ₹211.6 crore, up 16.5% YoY (Q2 FY26: ₹181.7 crore) - Q2 FY27 Adjusted EBITDA: ₹38.2 crore, margin 18.0% - Q2 FY27 Adjusted PBT: ₹43.6 crore, margin 24.0% - Q2 FY Q2 FY27 Adjusted EBITDA: ₹42.5 crore, up 11.3% YoY; EBITDA margin: 20.1% (down from 21.0%) - Q2 FY27 Adjusted PAT: ₹32.3 crore, up 13.4% YoY; PAT margin: 15.3% (down from 15.7%) - Q2 FY27 Adjusted PBT

From RPG Life Sciences Ltd's Q2 FY27 earnings-call transcript · updated 30 Oct 2026.

How did RPG Life Sciences' revenue grow in the September 2026 quarter?

- Q2 FY27 Revenue from Operations: ₹211.6 crore, up 16.5% YoY (Q2 FY26: ₹181.7 crore) - Q2 FY27 Adjusted EBITDA: ₹38.2 crore, margin 18.0% - Q2 FY27 Adjusted PBT: ₹43.6 crore, margin 24.0% - Q2 FY27 Adjusted PAT: ₹28.5 crore, margin 15.3% - Business segment Q2 FY27 sales (₹ crore) and YoY growth: • Domestic Formulations: ₹145.7 (+11.6%) • International Formulations: ₹36.7 (+6.4%) • API: ₹28.0 (+89.2%) - H1 FY27 Revenue from Operations: ₹407.3 crore, up 16.2% YoY (H1 FY26: ₹350.6 crore) - H1 FY27 business segment sales and YoY growth: • Domestic Formulations: ₹278.3 (+13.0%)

2 more points from RPG Life Sciences Ltd's call on revenue

Create a free account to keep reading this call

What happened to RPG Life Sciences' margins in Q2 FY27?

See what RPG Life Sciences Ltd said on profitability & margins — free account, 30 seconds.

What capex is RPG Life Sciences planning?

  • API & Intermediates Expansion:
  • Acquisitions: Actis Generics and Raghava Life Sciences added advanced intermediates capabilities and modern API manufacturing facilities (Page 16).
  • Strategic capital commitment of ₹700 crore created with PE partner InvAscent (Page 16).
  • Manufacturing Facilities Upgrades:
  • Domestic Formulations plant modernization and capacity expansion in progress to boost efficiency and scalability:
  • F1 Unit: capacity of 177 crore tablets and 88.5 lakh bottles annually (Page 14).

2 more points from RPG Life Sciences Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is RPG Life Sciences raising money or cutting debt?

See what RPG Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is RPG Life Sciences' order book?

See what RPG Life Sciences Ltd said on order book & pipeline — free account, 30 seconds.

RPG Life Sciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

RPG Life Sciences Ltd Q2 FY27 results — key figures

RPG Life Sciences Ltd Q2 FY27 reported results vs Q2 FY26, ₹ crore
₹ CrQ2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue212182+16.5%196+8.2%
Operating profit (EBITDA)4039+2.6%44-9.1%
Operating margin19%21%-2 pp22%-3 pp
Profit before tax3749-24.5%41-9.8%
Net profit (PAT)2837-24.3%31-9.7%
EPS (₹)16.0822.28-27.8%18.49-13%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹212 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

More Q2 FY27 results in Pharmaceuticals & Biotechnology

All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

RPG Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were RPG Life Sciences Ltd Q2 FY27 results?

RPG Life Sciences reported net profit of ₹28 Cr (−24.3% YoY) on revenue of ₹212 Cr (+16.5% YoY) in Q2 FY27.

What is RPG Life Sciences Ltd share price analysis?

RPG Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 42.6 with a market cap of ₹4,968 Cr. Investors should review the full earnings analysis for detailed insights.

Is RPG Life Sciences Ltd planning capital expenditure?

API & Intermediates Expansion: - Acquisitions: Actis Generics and Raghava Life Sciences added advanced intermediates capabilities and modern API manufacturing facilities (Page 16).

Keep RPG Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.